Skip to main content
Fig. 4 | BMC Urology

Fig. 4

From: Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

Fig. 4

Proportion of patients in ITT population with improved, stable or worsened QoL of the scales with greatest impairment at baseline. QoL quality of life, ITT intention-to-treat. For each scale at each postbaseline assessment, proportion of patients with improved or stable scores was compared using the Fisher’s exact test

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us